Ananda Developments Plc - hapac® Update PR Newswire

12 June 2019


(“Ananda” or the “Company”)

hapac® Update

The directors of Ananda Developments PLC (NEX: ANA) are pleased to provide shareholders with the following update regarding hapac®.

Ananda owns 15% of Liberty Herbal Technologies Limited, the 100% owner of hapac®, a technology for inhaling medicinal cannabis.

As previously announced, the hapac® product was launched in Milan, Italy over the Christmas and New Year period 2018/2019.    Since the last update in April 2019:

•             hapac® continues to be sold in 6 stores in Italy

•             hapac® products have been launched online on the Easyjoint e-shop

•             A new range of products have been developed and launched

•             Sales have increased significantly since January 2019

•             Plans are in place to launch a website and e-shop and further expand distribution.

Further information on the hapac® product can be found at

The directors of the Company accept responsibility for the contents of this announcement.


Ananda Developments PLC          +44 (0)7392 696 517
Chief Executive Officer
Melissa Sturgess

Investor Relations
Jeremy Sturgess-Smith

Peterhouse Capital Limited       +44 (0)20 7469 0930

Corporate Finance
Mark Anwyl
Fungai Ndoro

Corporate Broking
Lucy Williams
Duncan Vasey

Notes to editors

About Ananda Developments PLC

Ananda Developments invests in the developing market for medical or therapeutic Cannabis derivatives, or related products, including but not limited to nutraceuticals, dietary supplements and cosmetic products which contain Cannabis or hemp derived cannabinoids. The Directors believe that this market is growing due to an increasing number of states in the USA, as well as other countries around the world, changing their laws to allow for products containing constituents of Medical Cannabis to be developed, approved and sold.

A copy of the Company’s Admission Document is available at 

Ananda’s investment strategy is to invest in companies, projects or products that are progressing medical or therapeutic Cannabis research and development, or seeking to produce or cultivate Cannabis in any jurisdiction in which it is legal to do so, or are developing or have already developed, products that contain Cannabis derived cannabinoids and require funding to progress work plans or commercialise products.